<DOC>
	<DOCNO>NCT01668667</DOCNO>
	<brief_summary>Gabapentin enacarbil ( GEn ; GSK1838262 ; HORIZANT ) , dose 600 mg/day , currently approve United States treatment adult moderate-to-severe primary Restless Legs Syndrome ( RLS ) . The aim study compare efficacy , tolerability , safety GEn low dos ( 450 300 mg/day ) well already approve dose 600 mg/day versus placebo treatment subject moderate severe primary RLS . This study conduct post-marketing commitment ( PMC ) condition approval HORIZANT tablet ( NDA 022399 ) .</brief_summary>
	<brief_title>Gabapentin Enacarbil ( GSK1838262 ) Adult Restless Leg Syndrome Post Marketing Commitment Study</brief_title>
	<detailed_description>This Phase IV randomize , double-blind , placebo-controlled , fixed-dose , parallel group study assess efficacy , tolerability , safety 3 dos GEn ( 600 , 450 , 300 mg/day ) compare placebo treatment subject moderate-to-severe primary RLS . The study include 9 visit approximately 14 week eligible subject include 1-week Screening Period , 12-week Treatment Period , 1 week Follow Period . Screening occur within 1 week first schedule dose study medication . The total duration study , first subject enrol last subject complete approximately 2 year . Eligible subject ( least 18 year age ) must : - diagnosis RLS accord IRLSSG Diagnostic Criteria - history RLS symptoms least 15 night prior month , treatment , frequency symptom treatment start - document RLS symptom least 4 7 consecutive evenings/nights Screening Period , total RLS severity score least 15 International Restless Legs Syndrome ( IRLS ) Rating Scale screen baseline visit Approximately 498 subject enrol , randomly assign treatment group , receive study medication daily 12 week . Subjects randomly assign receive 1 4 follow treatment group ratio 1:1:1:1 : - GEn 600 mg/day - GEn 450 mg/day - GEn 300 mg/day - Matching placebo Subjects instruct take study medication daily food even approximately 5 PM . Each tablet must swallow whole divide , crush , chew . Each subject , regardless treatment assignment , take 3 tablet study medication ( 1 tablet Bottle A , 1 tablet Bottle B , 1 tablet Bottle C ) daily continue end Treatment Period ( Week 12 ) . Subjects return study site follow-up visit ( Visit 9 , Week 13 ) approximately 1 week last dose study medication . Each subject 's participation study approximately 14 week unless withdraw early study . For subject complete study , Visit 9 ( occur Day 86 92 ) consider end-of-study visit .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Men woman 18 year age old History RLS symptoms least 15 nights/month Documented RLS symptom , use 7day RLS Symptom Record , least 4 7 consecutive evenings/nights night Total RLS severity score 15 great International RLS ( IRLS ) Rating Scale Visit 1 Visit 2 Discontinuation dopamine agonist and/or gabapentin , treatment RLS ( e.g . opioids , benzodiazepine ) least 2 week prior Baseline If take prescription medication , therapy must stabilize least 3 month prior Screening anticipate change duration study Female subject eligible nonchildbearing potential lactating , negative pregnancy , agree use highly effective method avoid pregnancy Body mass index 34 Estimated creatinine clearance â‰¥60 mL/min Provides write consent accordance applicable regulatory requirement History sleep disorder may affect assessment RLS History RLS symptom augmentation endofdose rebound previous dopamine agonist treatment Neurologic disease movement disorder Other medical condition drug therapy could affect RLS efficacy assessment may present safety concern Have clinically significant unstable medical condition Have active suicidal plan/intent active suicidal thought past 6 month ; history suicide attempt</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>gabapentin enacarbil</keyword>
	<keyword>Horizant</keyword>
</DOC>